BMY
Bristol-Myers Squibb Company
Drug Manufacturers - General · Healthcare · United States
61.39
close · 2026-10-29
value
86
cheaper than peers86
quality
69
stronger fundamentals69
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | 9.2% | 95 |
| earnings yield, 2 years ago | 6.0% | 93 |
| cash flow yield, 2 years ago | 9.7% | 93 |
| cash flow yield, 1 year ago | 10.7% | 93 |
| cash flow yield, latest year | 9.9% | 93 |
| forward P/E | 9.28× | 87 |
| earnings yield, latest year | 5.4% | 86 |
| earnings yield, 3 years ago | 4.6% | 84 |
| EV to EBITDA | 8.33× | 78 |
| price to sales | 2.55× | 64 |
| price to book | 5.62× | 29 |
| earnings yield, 1 year ago | -6.9% | 24 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 46.6% | 96 |
| operating margin | 34.4% | 96 |
| revenue growth | 5.7% | 40 |
| debt to equity | 201.9% | 12 |
4 of 4 measures available
Facts
| market cap | $125B |
| free cash flow | $8.11B |
| employees | 32,500 |
| first trade | 1972-06-01 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 3.46 | -4.41 | 3.86 | 2.95 |
| free cash flow | $12.85B | $13.94B | $12.65B | $11.95B |
| net income | $7.05B | -$8.95B | $8.03B | $6.33B |
| revenue | $48.20B | $48.30B | $45.01B | $46.16B |
| unusual items | -$4.71B | -$13.93B | -$873.0M | -$2.19B |